Neoadjuvant Therapy Strategies in Rectal Cancer Management

Neoadjuvant therapy has transformed the management of locally advanced rectal cancer by delivering systemic and local treatments before surgery, with the dual aims of tumour downstaging and sphincter preservation. Standard approaches combine radiotherapy with fluoropyrimidine-based chemotherapy, achieving substantial reductions in tumour size and facilitating total mesorectal excision (TME) with clear margins. Over the past decade, attention has shifted towards intensifying systemic control through total neoadjuvant therapy (TNT), in which full-dose chemotherapy is administered either before or after chemoradiation but prior to surgery. Such regimens have shown promise in increasing pathological complete response rates, reducing distant metastases and offering organ-preserving non-operative management in selected patients. Advances in immunotherapy, targeted radiosensitisers and nanomedicine aim to overcome radioresistance, while functional imaging and molecular profiling inform adaptive treatment strategies. Concurrently, artificial intelligence and radiomics applied to multiparametric MRI and CT data have enabled accurate tumour segmentation and prediction of treatment response, supporting personalised de-escalation or intensification of neoadjuvant regimens. Collectively, these developments underscore a global trend towards precision medicine in rectal cancer, balancing oncological efficacy with quality-of-life outcomes.

Research from Nature Portfolio

Deep learning approaches have been developed to automate the localisation and contouring of rectal tumours on multiparametric MRI. Convolutional neural networks trained on annotated T2-weighted and diffusion-weighted images achieved high voxel-wise accuracy, markedly reducing interobserver variability and accelerating image analysis workflows. Separately, radiomics models combined high-dimensional features from planning CT scans with clinical variables to predict pathological complete response after chemoradiation. A deep neural network integrating radiomic signatures outperformed conventional stage-based prediction, correctly identifying complete responders in approximately four out of five patients. These studies illustrate the potential of machine learning to refine risk stratification, guide organ-saving approaches and tailor neoadjuvant protocols according to individual tumour biology and imaging phenotypes.

Neoadjuvant Therapy Strategies in Rectal Cancer Management publication trend

The graph below shows the total number of articles in neoadjuvant therapy strategies in rectal cancer management across all publications each year (not limited to Nature Index journals).

Technical terms

Neoadjuvant therapy: Preoperative treatment combining chemotherapy and/or radiotherapy to shrink tumours before surgical resection.

Total mesorectal excision (TME): Standardised surgical technique involving en bloc removal of the rectum and its mesentery to minimise local recurrence.

Pathological complete response (pCR): Absence of viable cancer cells in the resected specimen following neoadjuvant treatment, associated with favourable prognosis.

Radiomics: Extraction of quantitative imaging features from radiological data to characterise tumour phenotype and predict treatment outcomes.

PD-1 blockade: Immunotherapeutic strategy that inhibits the programmed death-1 pathway to enhance antitumour immune responses during chemoradiation.

References

1. Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study. Signal Transduction and Targeted Therapy (2024).
2. Radioresistance in rectal cancer: can nanoparticles turn the tide?. Molecular Cancer (2025).
3. Deep Learning for Fully-Automated Localization and Segmentation of Rectal Cancer on Multiparametric MR. Scientific Reports (2017).
4. Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer. Scientific Reports (2018).
5. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery. Annals of Surgery (2023).